Preet Singh, MD
Hematology & Oncology · Springfield, ILNPI 1881859833
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,755 of the $10,892 with a category attached, or 62.0%. 31 manufacturers reported payments, led by Novartis at 44.0% of the total. Reporting peaked in 2019 at $4,681 and has fallen 64.8% since, to $1,646 in 2025.
Across 111 payments — averaging $98.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$5K
- Incyte Corporation$2K
- Rigel Pharmaceuticals, Inc.$1K
- Eli Lilly$813
- Daiichi Sankyo Inc.$253
- AstraZeneca$237
- plus $2K from 25 others
Across 189 payments — averaging $20,812 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1.2M
- Merck$1.1M
- Eli Lilly$831K
- Genentech, Inc.$689K
- Janssen Research & Development, LLC$80K
- Pfizer$75K
- plus $27K from 3 others
What the payments were for
- Consulting fees$6,75562%
- Speaking & faculty fees$1,0009%
- Travel & lodging$6516%
- Food & beverage$2,31921%
- Education$1682%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 14 | $4,796 |
| Incyte Corporation | 2 | $2,199 |
| Rigel Pharmaceuticals, Inc. | 1 | $1,000 |
| Eli Lilly | 2 | $813 |
| Daiichi Sankyo Inc. | 10 | $253 |
| AstraZeneca | 13 | $237 |
| Johnson & Johnson | 8 | $215 |
| Gilead | 12 | $202 |
| Astellas Pharma US Inc | 5 | $191 |
| Merck | 9 | $174 |
| E.r. Squibb & Sons, L.L.C. | 3 | $133 |
| EMD Serono, Inc. | 4 | $98 |
| US Oncology Corporate, Inc. | 2 | $57 |
| Jazz Pharmaceuticals Inc. | 2 | $54 |
| Genmab U.S., Inc. | 2 | $52 |
| Regeneron Healthcare Solutions, Inc. | 2 | $47 |
| Exelixis Inc. | 2 | $40 |
| Mirati Therapeutics, Inc. | 2 | $40 |
| Pfizer | 3 | $35 |
| Bristol Myers Squibb | 2 | $32 |
| AbbVie | 1 | $31 |
| Seagen Inc. | 1 | $27 |
| Myriad Genetic Laboratories, Inc. | 1 | $26 |
| Janssen Scientific Affairs, LLC | 1 | $22 |
| Amgen | 1 | $21 |
| Bayer | 1 | $21 |
| Array Biopharma Inc | 1 | $20 |
| Tempus AI, Inc | 1 | $15 |
| Genentech, Inc. | 1 | $14 |
| AVEO Pharmaceuticals, Inc. | 1 | $13 |
| ADC Therapeutics America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,892 in reported general payments places this provider in the 70th percentile of 580 hematology & oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 61 | $1,131,549 |
| IbrancePalbociclib | 25 | $391,045 |
| RevlimidLenalidomide | 20 | $361,185 |
| BrukinsaZanubrutinib | 14 | $331,568 |
| CalquenceAcalabrutinib Maleate | 15 | $313,044 |
| TagrissoOsimertinib Mesylate | 13 | $224,428 |
| Imatinib Mesylate | 25 | $164,247 |
| EliquisApixaban | 64 | $37,961 |
| XgevaDenosumab | 12 | $36,348 |
| Anastrozole | 264 | $4,088 |
| Exemestane | 20 | $3,106 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 86 | $1,560 |
| Colestipol Hcl | 23 | $931 |
| Ondansetron Hcl | 110 | $793 |
| Ondansetron OdtOndansetron | 43 | $778 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $191 | $1,131,54961 claims |
| AstraZenecaCalquence, Tagrisso | $237 | $537,47328 claims |
| PfizerIbrance, Eliquis | $35 | $429,00689 claims |
| Bristol Myers SquibbRevlimid | $32 | $361,18520 claims |
| AmgenXgeva | $21 | $36,34812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 580 hematology & oncology providers in Illinois.
Other hematology & oncology in Springfield
- Mohamad Khair KhasawnehMaywood$998K
- Michael BishopChicago$974K
- Jamile ShammoChicago$910K
- John BerryBerwyn$687K
- Young Kwang ChaeChicago$563K
- Irfan MirzaChicago$544K
- Marina GarassinoChicago$397K
- Tulio RodriguezZion$337K
- Chih-Yi LiaoChicago$317K
- Gary KayElk Grove Village$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.